Mumbai-based SMT (Sahajanand Medical Technologies), a global leader in innovative cardiovascular solutions, has announced the launch of its Hydra Transcatheter Aortic Valve Implantation (TAVI) system in Russia.
Hydra introduces a highly refined approach to managing severe aortic stenosis, providing physicians with a dependable and innovative option for high-risk patients who are not candidates for open-heart surgery.
TAVI procedures are increasingly gaining traction in Russia as an effective, minimally invasive solution for severe aortic stenosis. Hydra has been designed to meet the unique clinical needs of this growing patient population, reflecting SMT’s ongoing commitment to advancing healthcare through technology.
“Russia’s medical community has shown significant interest in adopting TAVI technologies, and Hydra is a meaningful addition to the solutions available for treating complex cases,” said Sergey Antonov, Head of Commercial Operations for Russia. “Our entry into the market reinforces SMT’s dedication to supporting physicians with devices that combine precision, flexibility, and reliability.”
Hydra enters the Russian market at a pivotal time, with TAVI gaining widespread recognition for its ability to address complex cardiac cases. SMT’s presence in Russia, established through its successful Supraflex Cruz drug-eluting stent system, now expands to structural heart disease solutions with Hydra.
